OCM Life Sciences Portfolio LP /
Xencor, Inc.
OCM Life Sciences Portfolio LP to Purchase Xencor Royalty Rights
What happened
OCM Life Sciences Portfolio LP agreed to purchase certain past and potential royalties tied to Ultomiris® from Xencor, Inc. The agreement includes an upfront payment of $192.5 million.
The royalty purchase agreement also covers royalty rights tied to Monjuvi®/Minjuvi® for an upfront payment of $22.5 million.
The source
Everything on this page comes from the source below.
OCM Life Sciences Portfolio LP to Purchase Xencor Royalty Rights
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly